top of page
KELLY
OFFICIAL TITLE: A PHASE II STUDY OF PEMBROLIZUMAB AND ERIBULIN IN PATIENTS WITH HRPOSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES.
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
AACR 2018 – DOWNLOAD THE POSTER
SABCS 2019 – DOWNLOAD THE POSTER
CLINICAL TRIAL DETAILS
THIS A MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO ASSESS THE EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH ERIBULIN IN FEMALE PATIENTS OLDER THAN 18 YEARS OLD WITH HORMONE RECEPTOR-(HR)POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH AT LEAST ONE, BUT NOT MORE THAN TWO, PRIOR CHEMOTHERAPEUTIC REGIMENS FOR TREATMENT OF LOCALLY RECURRENT AND/OR METASTATIC DISEASE. PRIOR THERAPY MUST HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE. PRIOR ANTI-HORMONAL THERAPY IN THE METASTATIC DISEASE SETTING IS MANDATORY.
​
THE NUMBER OF PATIENTS TO BE INCLUDED IS 44 PATIENTS AT 11 SITES. ALL ELIGIBLE PATIENTS WILL BE TREATED WITH MK3475 (PEMBROLIZUMAB) 200 MG ON DAY 1 OF EACH 21-DAY CYCLE AND ERIBULIN 1.23 MG/M2 (EQUIVALENT TO ERIBULIN MESYLATE AT 1.4 MG/M2) ON DAYS 1 AND 8 OF EVERY 21-DAY CYCLE.
​
KELLY AT CLINICALTRIALS.GOV
​
RESULTS OF THE KELLY STUDY
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
BREAST
II
44
11
Spain
Closing
KELLY SITES
SPAIN
Hospital Clínico Universitario de Valencia
SPAIN
Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona
SPAIN
Hospital Parc Taulí
SPAIN
Hospital Clínic i Provincial de Barcelona
SPAIN
MD Anderson Cancer Center Madrid
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Complejo Hospitalario de Navarra
SPAIN
Complejo Hospitalario Universitario A Coruña (CHUAC)
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Hospital Clínico Universitario Virgen de la Arrixaca
SPAIN
Hospital Arnau de Vilanova de Valencia
bottom of page